ProKidney Corp. (PROK) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 15, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PROK SEC filings page.
ProKidney Corp. (PROK) reported $818K in revenue over the twelve months to Jun 30, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
ProKidney remains a development-stage business: research spending dwarfs revenue, while operations consume cash against a liability-heavy balance sheet.
In FY2025, operating cash outflow reached$120M versus a net loss of$69M , while free cash flow was-$135M after$15.2M of capital spending. That gap means reported earnings understate the cash required to fund current operations and development activity.
The move from FY2024 revenue of
FY2025 liabilities of
Financial Health Signals
ProKidney Corp. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
ProKidney Corp. scores -5.89, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($307.1M) relative to total liabilities ($1.3B). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
ProKidney Corp. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
ProKidney Corp. reported a net loss of $69.0M while operations used $120.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
ProKidney Corp. reported an operating loss of $165.0M against $4K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
ProKidney Corp. generated $150K in revenue in Q2 2026. This represents a decrease of 32.1% from the same quarter a year earlier. Against the prior quarter it is down 33.6%.
ProKidney Corp.'s EBITDA was -$46.9M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 22.8% from the same quarter a year earlier. Against the prior quarter it is down 8.4%.
ProKidney Corp. reported -$28.4M in net income in Q2 2026. This represents a decrease of 71.7% from the same quarter a year earlier. Against the prior quarter it is down 41.8%.
Not reported for Q2 2026.
Cash & Balance Sheet
ProKidney Corp. recorded an outflow of $44.2M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 28.0% from the same quarter a year earlier. Against the prior quarter it is up 2.8%.
ProKidney Corp. held $74.9M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q2 2026.
Capital Allocation
ProKidney Corp. invested $36.1M in research and development in Q2 2026. This represents an increase of 39.5% from the same quarter a year earlier. Against the prior quarter it is up 6.7%.
ProKidney Corp. invested $3.8M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 23.2% from the same quarter a year earlier. Against the prior quarter it is up 1.3%.
Not reported for Q2 2026.
PROK Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $150K-32.1% | $226K-1.7% | $225K | $217K | $221K | $230K | N/A | $0 |
| R&D Expenses | $36.1M+39.5% | $33.8M+24.1% | $34.2M | $26.8M-14.2% | $25.9M-12.0% | $27.3M+0.1% | N/A | $31.3M-2.9% |
| SG&A Expenses | $12.4M-11.5% | $11.3M-21.2% | $11.4M | $11.9M-32.7% | $14.0M+2.9% | $14.4M+11.8% | N/A | $17.7M+22.9% |
| Operating Income | -$48.4M-21.8% | -$44.9M-8.6% | -$45.4M | -$38.5M+21.3% | -$39.7M+7.8% | -$41.4M-3.3% | N/A | -$49.0M-5.1% |
| EBITDA | -$46.9M-22.8% | -$43.3M-8.8% | -$43.3M | -$37.1M+22.3% | -$38.2M+9.2% | -$39.8M-2.1% | N/A | -$47.8M-4.4% |
| Interest Expense | $1K0.0% | $15K | $1K | $2K0.0% | $1K-66.7% | $0-100.0% | N/A | $2K0.0% |
| Income Tax | $0-100.0% | $0-100.0% | -$1.6M | $560K+123.9% | $848K+1614.3% | $591K+503.1% | N/A | -$2.3M-356.5% |
| Net Income | -$28.4M-71.7% | -$20.0M-19.7% | -$19.2M | -$16.5M+8.0% | -$16.6M-32.4% | -$16.7M-76.3% | N/A | -$17.9M-63.1% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
PROK Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $249.0M-33.1% | $292.8M-27.9% | $335.6M-23.9% | $351.6M-25.9% | $372.1M-25.4% | $406.1M+4.7% | $441.1M+4.9% | $474.8M+5.1% |
| Current Assets | $189.8M-41.5% | $234.9M-34.7% | $280.7M-29.1% | $300.0M-30.3% | $324.4M-27.9% | $359.7M+5.7% | $395.9M+5.8% | $430.2M+5.9% |
| Cash & Equivalents | $74.9M-11.9% | $101.9M+4.2% | $108.5M+9.5% | $95.3M-11.8% | $84.9M-60.4% | $97.8M+15.9% | $99.1M+63.4% | $108.1M-43.5% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $1.1B-17.6% | $1.3B-6.3% | $1.3B-6.2% | $1.4B-6.5% | $1.4B-6.6% | $1.4B-5.3% | $1.4B-5.8% | $1.5B-5.8% |
| Current Liabilities | $22.7M-19.6% | $25.9M-21.0% | $30.7M-15.1% | $29.1M+15.4% | $28.3M+37.3% | $32.8M+70.0% | $36.2M+44.6% | $25.2M+20.0% |
| Non-Current Liabilities | $1.1B-17.6% | $1.3B-5.9% | $1.3B-6.0% | $1.3B-6.9% | $1.3B-7.2% | $1.4B-6.3% | $1.4B-6.6% | $1.4B-6.2% |
| Total Equity | -$883.5M+11.9% | -$1.0B-2.5% | -$1.0B-1.6% | -$1.0B-2.9% | -$1.0B-3.1% | -$998.6M+8.9% | -$995.0M+9.8% | -$979.7M+10.3% |
| Retained Earnings | -$1.3B-6.8% | -$1.3B-5.9% | -$1.3B-5.7% | -$1.3B-6.0% | -$1.2B-6.2% | -$1.2B-6.0% | -$1.2B-5.4% | -$1.2B-4.0% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
PROK Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$40.4M-28.5% | -$41.7M-40.9% | -$32.5M-34.5% | -$26.6M+9.0% | -$31.4M+18.0% | -$29.6M+14.6% | -$24.2M+4.8% | -$29.2M-23.0% |
| Depreciation & Amortization | $1.4M-2.8% | $1.7M+3.6% | $1.8M+16.7% | $1.4M+16.6% | $1.5M+54.7% | $1.6M+45.2% | $1.6M+37.3% | $1.2M+39.3% |
| Stock-Based Compensation | $5.6M-14.5% | $4.9M-22.9% | N/A | $6.7M-3.7% | $6.5M-16.2% | $6.4M-16.4% | N/A | $6.9M-46.6% |
| Capital Expenditures | $3.8M+23.2% | $3.8M+233.5% | $5.8M-77.5% | $5.2M+116.2% | $3.1M+389.3% | $1.1M+18.2% | $25.5M+1522.7% | $2.4M-91.4% |
| Free Cash Flow | -$44.2M-28.0% | -$45.5M-48.0% | -$38.3M+23.0% | -$31.8M-0.5% | -$34.5M+11.3% | -$30.7M+13.7% | -$49.7M-84.3% | -$31.6M+38.8% |
| Investing Cash Flow | $12.8M-31.0% | $34.8M+23.1% | $28.1M+86.3% | $29.0M+135.5% | $18.6M-35.0% | $28.3M-51.6% | $15.1M+115.7% | -$81.6M-187.7% |
| Financing Cash Flow | $541K+3964.3% | $215K+1891.7% | $17.6M+14236.6% | $8.0M+78.7% | -$14K-100.0% | -$12K+7.7% | $123K+101.3% | $4.5M+34376.9% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
PROK Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -32248.7% | -19881.9% | -20164.9% | -17759.9% | -17967.9% | -17994.8% | N/A | N/A |
| Net Margin | -18948.0% | -8865.9% | -8547.1% | -7589.4% | -7489.6% | -7275.7% | N/A | N/A |
| Return on Assets | -11.4%-7.0pp | -6.8%-2.7pp | -5.7% | -4.7%-0.9pp | -4.5%-1.9pp | -4.1%-1.7pp | N/A | -3.8%-1.3pp |
| Current Ratio | 8.36-3.1x | 9.06-1.9x | 9.13-1.8x | 10.32-6.8x | 11.48-10.4x | 10.96-6.7x | 10.93-4.0x | 17.09-2.3x |
| Asset Turnover | 0.000.0x | 0.000.0x | 0.00 | 0.000.0x | 0.000.0x | 0.000.0x | N/A | 0.00 |
| FCF Margin | -29471.3% | -20119.0% | -17006.7% | -14651.2% | -15623.5% | -13359.6% | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Return on Equity, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$1.0B), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| ProKidney Corp. PROK | FY2025 | $893K | -$69.0M | N/A | $307.1M | — |
| Sarepta Therapeutics,, Inc. SRPT | FY2025 | $2.2B | -$713.4M | -32.5% | $1.8B | 44/100 |
| Dyne Therapeutics, Inc. DYN | FY2025 | N/A | -$446 | N/A | $2.8B | — |
| Aurinia Pharmaceuticals Inc AUPH | FY2025 | $283.1M | $287.2M | N/A | $2.2B | 56/100 |
| Ardelyx, Inc. ARDX | FY2025 | $407.3M | -$62.0M | -15.2% | $823.6M | 45/100 |
| Mesoblast Limited MESO | FY2025 | $17.2M | -$102.1M | N/A | $1.8B | 28/100 |
Where ProKidney Corp. Ranks
Frequently Asked Questions
What is ProKidney Corp.'s annual revenue?
ProKidney Corp. (PROK) reported $893K in total revenue for fiscal year 2025. This represents a 1075.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is ProKidney Corp.'s revenue growing?
ProKidney Corp. (PROK) revenue grew by 1075.0% year-over-year, from $76K to $893K in fiscal year 2025.
Is ProKidney Corp. profitable?
No, ProKidney Corp. (PROK) reported a net income of -$69.0M in fiscal year 2025.
What is ProKidney Corp.'s EBITDA?
ProKidney Corp. (PROK) had EBITDA of -$158.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is ProKidney Corp.'s free cash flow?
ProKidney Corp. (PROK) recorded an outflow of $135.3M in free cash flow during fiscal year 2025. This represents a 13.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is ProKidney Corp.'s operating cash flow?
ProKidney Corp. (PROK) recorded an outflow of $120.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are ProKidney Corp.'s total assets?
ProKidney Corp. (PROK) had $335.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are ProKidney Corp.'s capital expenditures?
ProKidney Corp. (PROK) invested $15.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does ProKidney Corp. spend on research and development?
ProKidney Corp. (PROK) invested $114.1M in research and development during fiscal year 2025.
What is ProKidney Corp.'s current ratio?
ProKidney Corp. (PROK) had a current ratio of 9.13 as of fiscal year 2025, which is generally considered healthy.
What is ProKidney Corp.'s return on assets (ROA)?
ProKidney Corp. (PROK) had a return on assets of -20.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is ProKidney Corp.'s P/E ratio?
ProKidney Corp. (PROK) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $307.1M as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is ProKidney Corp.'s price-to-sales ratio?
ProKidney Corp. (PROK) trades at 375x sales, its market capitalization divided by revenue of $818K revenue, trailing 12 months to June 30, 2026. The market capitalization is $307.1M as of Oct 15, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does ProKidney Corp.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, ProKidney Corp. (PROK) held $108.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $120.1M over that year. Dividing the one by the other, the reported balance equals about 11 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is ProKidney Corp.'s debt-to-equity ratio negative or not reported?
ProKidney Corp. (PROK) has negative shareholder equity of -$1.0B as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is ProKidney Corp.'s Altman Z-Score?
ProKidney Corp. (PROK) has an Altman Z-Score of -5.89, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is ProKidney Corp.'s Piotroski F-Score?
ProKidney Corp. (PROK) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are ProKidney Corp.'s earnings high quality?
ProKidney Corp. (PROK) reported a net loss of $69.0M while operations used $120.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can ProKidney Corp. cover its interest payments?
ProKidney Corp. (PROK) reported an operating loss of $165.0M against $4K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.